'clerking team that exhibits 'perfect communication''
Legal 500 2008
'A veritable powerhouse of IP expertise'
Chambers and Partners 2011
'8 New Square successfully parlays its renowned IP expertise into success in the IT sector.'
Chambers & Partners (Information Technology) 2009
'outstanding IP chambers'
Legal 500 2008
'Practical and helpful clerks" provide a "smooth and personable service.'
Chambers and Partners 2011
'A number of great IT and telecoms barristers.'
Legal 500 2010
'excellence on IT matters'
Legal 500 (Information Technology) 2010
'An incredibly good set for IP matters'.
Legal 500 2010
'Top drawer IP set.'
Legal 500 2010
Generics (UK) Ltd (trading as Mylan) v Novartis AG
Case Summary | 30 September 2011
Daniel Alexander QC and Henry Ward acted for Generics (UK) Limited in a claim for revocation of an SPC (and associated patent) in relation to the active ingredient of the Alzheimer’s drug rivastigmine. The patent was to the enantiomer of a previously disclosed compound, RA7. Novartis alleged that the skilled man would have perceived there to be no benefit to resolving RA7 which was still at an early stage of drug development, and thus the separation of the enantiomer was inventive. The trial was expedited and came on in the space of just two months over the long vacation, taking place in the first week of September 2011. The patent and SPC were successfully revoked by Generics, Floyd J finding that it the alleged invention was obvious over the prior art as at 1987.